About Careers MedBlog Contact us

Suven Life Sciences Secures Patents in Europe and Hong Kong for Neurological Drug

by Shirley Johanna on May 14, 2015 at 6:27 PM
Font : A-A+

Suven Life Sciences Secures Patents in Europe and Hong Kong for Neurological Drug

The Hyderabad-based pharmaceutical firm Suven Life Sciences announced on May 13 that the firm has been granted patents in Europe and Hong Kong for a drug used in the treatment of neurodegenerative diseases like Alzheimer's, Schizophrenia and Parkinson's.

The firm said during the trading hours at the Bombay Stock Exchange, "One product patent from Europe and one product patent from Hong Kong corresponding to the new chemical entities for the treatment of disorders associated with neurodegenerative diseases".


Suven has a total of 16 granted patents from Europe and 17 from Hong Kong, including these two patents.

Venkat Jasti, CEO of Suven Life Sciences, said, "We are very pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS (central nervous system) arena that are being developed for cognitive disorders with high unmet medial need with huge market potential globally."

The granted patents are exclusive intellectual property of Suven and the products out of these inventions may be out-licensed at various phases of clinical development.

Source: Medindia


Recommended Reading

Latest Drug News

 Parkinson's Unmet Needs Creates Path for New Entrants into the Market
Addressing the unmet needs of Parkinson's Disease by providing disease-modifying therapies could bring about a major shift in the way that patients are treated.
How Microrobots Could Help Treat Bladder Diseases?
Microrobots could swirl through a person's blood stream, search for targeted areas to treat for various ailments.
How Can Multivitamin Supplements Slow Cognitive Aging?
Supplementation with multivitamins is an inexpensive way for older adults to slow down memory loss.
 Ivosidenib Approved for Acute Myeloid Leukemia & Advanced Cholangiocarcinoma
Some people with an aggressive blood cancer called acute myeloid leukemia (AML) may soon have a new drug option called Ivosidenib that blocks the activity of IDH1 gene.
Sacubitril/valsartan Unleashes Hope for Heart Failure Patients
In case of cardiac failure where the ejection fraction is greater than 40%, sacubitril/valsartan can prove to be quite beneficial
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

Suven Life Sciences Secures Patents in Europe and Hong Kong for Neurological Drug Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests